Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-75348780 + JNJ-80948543 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-75348780 | CD22 Immune Cell Therapy 15 CD3 Antibody 103 | JNJ-75348780 is a bi-specific antibody targeting CD3 and CD22, which may lead to cytotoxic immune response against B-cell tumors (NCI Thesaurus). | ||
JNJ-80948543 | JNJ 80948543|JNJ80948543 | CD3 Antibody 103 | JNJ-80948543 is an antibody that targets an undisclosed tumor-associated antigen (TAA) and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06660563 | Phase I | JNJ-75348780 + JNJ-80948543 | A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) | Recruiting | GBR | ESP | AUS | 1 |